The assessment of ERα α, PgR and HER2 status is routinely performed today to determine the endocrine responsiveness of breast cancer samples. Such determination is usually accomplished by means of immunohistochemistry and in case of HER2 amplification by means of fluorescent in situ hybridization (FISH). The analysis of these markers can be improved by simultaneous measurements using quantitative real-time PCR (Qrt-PCR). In this study we compared Qrt-PCR results for the assessment of mRNA levels of ERα α, PgR, and the members of the human epidermal growth factor receptor family, HER1, HER2, HER3 and HER4. The results were obtained in two independent laboratories using two different methods, SYBR Green I and TaqMan probes, and different primers. By linear regression we demonstrated a good concordance for all six markers. The quantitative mRNA expression levels of ERα α, PgR and HER2 also strongly correlated with the respective quantitative protein expression levels prospectively detected by EIA in both laboratories. In addition, HER2 mRNA expression levels correlated well with gene amplification detected by FISH in the same biopsies. Our results indicate that both Qrt-PCR methods were robust and sensitive tools for routine diagnostics and consistent with standard methodologies. The developed simultaneous assessment of several biomarkers is fast and labor effective and allows optimization of the clinical decision-making process in breast cancer tissue and/or core biopsies. (Int J Biol Markers 2006; 21: 30-9)
INTRODUCTION
Estrogen receptor alpha (ERα) and progesterone receptor (PgR) status are important determinants for the choice of systematic endocrine therapy of patients with breast cancer (BC). In this context the International St. Gallen Consensus Panel of 2003 and 2005 recommended diagnostic ER/PgR standardization with respect to high quality and reproducibility (1, 2) . Moreover, better understanding of acquired endocrine resistance (3) by clinical and laboratory investigations suggests that overexpression and/or amplification of HER2, a member of the human epidermal receptor (HER) family of receptor tyrosine kinases, decreases the probability of endocrine response through down-modulation of ERα and PgR (4) (5) (6) , as well as the response to adjuvant CMF therapy (7) . Such clinical and molecular aspects demonstrate that hormone receptor assessment is required but not yet sufficient to predict endocrine responsiveness.
ERα and PgR can be detected either by enzyme immunoassays (EIA) or by immunohistochemistry (IHC) (8, 9) , whereas the determination of HER2 can be performed by IHC (10) and EIA tests (11) , which have to be revalidated for gene amplification by fluorescent in situ hybridization (FISH) (12, 13) when the IHC results are ambiguous (14) . Subsequently, for each BC biopsy multiple tests have to be performed which have the disadvantage of being either semiquantitative (IHC), requiring a lot of tissue material (EIA) or being very laborious (FISH).
New developments in molecular biotechnology such as quantitative real-time PCR (Qrt-PCR) offer the possibility of multiparametric and quantitative analysis of mRNA expression levels of clinically relevant biomarkers for treatment of patients with BC. Such a methodological approach has been shown to allow accurate quantification of mRNA expression for ERα, PgR and HER2 when compared to protein expression (15) (16) (17) . We therefore developed a Qrt-PCR multi-gene assessment standard protocol for the quantification of ERα, PgR and HER2 as well as HER1/EGFR, HER3 and HER4, which are key biomarkers for treatment decision in BC (18, 19) .
This study was designed to assess and validate the reproducibility and robustness of the newly developed Qrt-PCR method for simultaneous detection with SYBR Green ® I as fluorescent dye of the mRNA expression levels of ERα, PgR and HER1-4, comparing it with serial detection of the transcript of the same genes in an independent diagnostic laboratory unit according to different laboratory protocols using marker-specific fluorescent probes. In addition, we investigated the correlations between mRNA expression levels and the respective clinically validated quantitative protein levels of ERα, PgR and HER2 as well as HER2 FISH results.
MATERIALS AND METHODS

Tumor tissue selection, characterization and processing
Tumor samples of 199 primary breast cancer patients were analyzed in this study. Fresh tumor tissue was kept on ice and subsequently examined by the pathologist, who selected a histologically representative specimen containing at least 65% tumor cells. All tissue samples were immediately thereafter either cryopreserved (-70°C) or stored in liquid nitrogen and subsequently powdered in liquid nitrogen prior to RNA and protein extraction. Set 1 comprised 100 samples cryopreserved immediately after surgical resection by the Stiftung Tumorbank Basel (Basel), Switzerland (Set 1a; n=50), or by the Laboratoire de Transfert d'Oncologie Biologique AP-HM, Marseille (MRS), France (Set 1b; n=50) with known ERα, PgR and in case of Set 1a HER2 protein expression levels detected at the time of surgery by the respective laboratories. Set 2 comprised 99 primary BC samples routinely analyzed by the laboratory in Basel for simultaneous quantitative mRNA expression levels of different genes by Qrt-PCR, and by the Institute of Pathology, University Hospital Basel, for HER2 amplification by FISH. The hormone receptors and HER2 status of the two collective sets are shown in Table I . Studies were approved by the respective ethical committees including written consent of each patient.
Cytosol extract preparation and immunoassay determinations of ERα, PgR and HER2 protein levels and FISH analysis
Tumor tissue homogenates were prepared from tumor set 1 according to standard protocols for ERα and PgR protein determinations as described (20) . Each of the laboratory units determined ERα and PgR protein levels in the patient samples they had contributed to the study (MRS: n=50; Basel: n=50). Total cytosolic protein concentrations were measured by the Bio-Rad Protein Kit (BIO-RAD, Munich, Germany). ERα and PgR protein levels were assessed with the ERα-and PgR-EIA Monoclonal Kits (Abbott Laboratories, Abbott Park, IL, USA). Quality control of ERα and PgR assays was carried out by the Receptor Biomarker Group (RBG) of the EORTC (21). Total protein levels of the particulate membrane fractions were measured with the BCA™ Protein Assay Reagent Kit and after dilution with the Micro BCA™ Protein Assay Reagent Kit (Pierce, Rockford, IL, USA). HER2 was only assessed in the 50 samples from Basel (Set 1a) with the HER2/neu Tissue Extract EIA kit (Chiron, Triton Diagnostics, Alameda, CA, USA) and revaluated with Oncogene Science Human HER2/neu Quantitative ELISA Kit (Bayer, Leverkusen, Germany). All tests were performed according to the manufacturer's recommendations.
FISH analysis was performed in the 99 tissues from tumor set 2 at the Institute of Pathology of the University Hospital, Basel as previously described (22) .
Extraction, quantification and quality control of RNA
Each of the laboratory units extracted total RNA from the samples they had contributed to the study (MRS: Set 1b, n=50; Basel: Set 1a and Set 2, n=149). RNAs from tumor set 1 were subsequently exchanged and all were analyzed by both laboratories with their respective techniques. Total RNA was extracted from powdered tissue sample aliquots using the RNeasy Mini Kit (Qiagen) (Basel) or the RNeasy 96 kit (Qiagen) automated on the BioRobot 8000 (Qiagen) (MRS), respectively, according to the manufacturer's recommendations. All RNA samples were quantified and checked for quality on the Bioanalyzer 2100 and the RNA 6000 Nano LabChip-Kit (Agilent Technologies) according to the manufacturer's recommendations. Purified RNAs were stored at -70˚C until use. One microgram of high-quality total RNA was reverse transcribed into complementary cDNA using 2 U of MMLV Reverse Transcriptase (Invitrogen), 10mM DDT, 1 µg hexamer primers, 40 U RNasin and 0.5mM of each dNTP (all Promega) and 1x reaction buffer in a final volume of 20 µL. RNA, hexamer primers and dNTPs were incubated for 5 minutes at 65˚C, cooled for 5 minutes at 4˚C and warmed for 10 minutes at 25˚C before the rest of the reaction mix was added. Reverse transcription was carried out at 37˚C for 50 minutes followed by 5 minutes at 42˚C. After the reaction 180 µL of H 2 O was added and cDNAs were stored at -20˚C until use.
Primers
Primers and probes (probes only in MRS) were designed using the Primer Express™ v2.0 software (Applied Biosystems, Foster City, CA, USA). All primer sequences were blasted against the dbEST database to confirm their specificity. Primers were ordered from GeneScan Europe (Freiburg, Germany). The primer sets were tested in Qrt-PCR reactions with universal human reference RNA (Stratagene, La Jolla, CA, USA). All amplicons were submitted to a temperature ramping, analyzed for their melting points and sequenced at the Medizinische Universitäts-Kinderklinik in Bern. Primers of Basel were selected to work at the same conditions (AT=60˚C) and to be cDNA specific. Primers of MRS were tested by SYBR Green I analysis prior to probe ordering. Primer and probe sequences are listed in Table II .
Q-PCR performed in Basel
PCR was performed in 40 cycles on an ABI Prism 7000 using the 2x SYBR Green ® I Master Mix (Applied Biosystems, Foster City, CA, USA) in a final volume of 25 µL. The primer concentration was 0.2 µM each. Data were normalized by subtracting the 18S rRNA Ct value. All Qrt-PCR results were subsequently expressed in arbitrary units per microgram reverse-transcribed RNA (U/µg rt-RNA). The six markers (ERα, PgR, HER1-4) were measured simultaneously on the same plate as singlet. The interassay variations were monitored on Human Universal Standard RNA (Stratagene) using GSTP1 (glutathione S-transferase-P1) as internal control gene. All assays were reproducible with an interassay standard deviation of 0.15 Ct among the different runs.
Q-PCR performed in MRS
The amplification mixture contained cDNA derived from 50 ng total RNA, 0.2 µM of primer, and 0.1 µM of TaqMan probe in 5 mM Mg 2+ . PCR was performed on an ABI Prism 7700 for 40 cycles. Denaturation was done at 94°C for 15 seconds, and annealing/extension at 57°C (PgR), 62°C (ERα), 63°C (HER1 and HER3), 65°C (HER2) and 67°C (HER4) for 20 seconds. All reactions were performed in triplicate and the variation coefficient of the intra-assay accuracy of amplification, calculated by dividing the standard deviation by the mean of all measurements, was 7% for ERα, 15% for PgR, 10% for HER1, 17% for HER2, 15% for HER3 and 10% for HER4. mRNA levels were normalized to the 18S rRNA levels 
Primers and probes were designed in Basel and MRS (23) for quantification. Specific RNAs which correspond to ERα, PgR and HER1 to 4 cDNA constructs were produced by in vitro transcription from linearized templates using T 7 or T 3 polymerases and calibrated by area-specific peak measurement with 2100 BioAnalyser (Agilent technologies). One microgram of specific RNA was reverse transcribed to cDNA and used to create standard curves. These curves were used to calibrate the amounts of each marker mRNA in MCF7, SKBR3 and T47D cell lines. In the final analysis we used T47D mRNA as calibrator for HER2 and HER4 and MCF7 mRNA for ERα, PgR, HER1 and HER3. As quality control we used SKBR3 and T47D for ERα, PgR, HER1 and HER3 and we used MCF7 and SKBR3 for HER2 and HER4. Adopting such experimental conditions, we obtained a linear relationship between the RNA concentration (previously transcribed into cDNA) and the fluorescent signal (∆RQ) for ERα, PgR, HER1 to 4, and 18S RNAs. For each unknown sample, we determined the ∆RQ values of the investigated genes and the results were expressed as fg specific mRNA / ng 18S rRNA.
Statistical analysis
The RNA expression levels detected in the two independent laboratories were compared by means of Passing and Bablok regression (24, 25) performed using MedCalc Software, Version 8.0 (Kagi 1442-A, Berkeley, CA, USA) and the correlation coefficients were calculated. mRNA levels and the respective quantitative protein expression levels were compared by Spearman's rank correlation. Differences between the median ERα and PgR levels in HER2-negative and positive tumors were assessed by means of the Mann-Whitney test. In tumor set 2 the performance of HER2 status determined by Qrt-PCR was assessed by means of receiver operating characteristics (ROC) curve with HER2 amplification detected by FISH as a reference, and by means of the chi-square test.
RESULTS
PCR optimization and validation
The PCR assays were optimized independently in Basel and MRS by applying different primers, detection methods, protocols, equipment and test performance. In Basel the expression of 70 genes was analyzed in all 199 samples (Set 1 and 2), including the six target genes and 18S, simultaneously as singlets on a 96-well plate (one patient per plate) together with GSTP1 from Human Universal Standard RNA (Stratagen) to supervise deviations between different assays. The linearity of ERα, PgR, HER1-4 and 18S assays was measured by serial dilution of pooled BC cDNA. Normalization (Ct target gene -Ct 18S) was done directly after every assay. MRS tested Set 1 by analyzing each gene separately in triplicate and on different plates (see "Materials and Methods"). In general, 25 patients were analyzed on one plate. All genes were first quantified based on standard curves generated using serial dilutions of reverse-transcribed gene-specific riboprobes before normalization with 18S.
Both Qrt-PCR detection methods permitted a linear quantification of each target gene ranging from five to six log dilutions. The PCR efficiency for ERα, PgR, HER1-4 and 18S was more than 90% in both laboratory units. In Basel the calculated mean standard deviations for interassay variability of ERα, PgR and HER1-4 were 0.2 to 0.4 cycles. The calculated mean standard deviations of triplicates in MRS were between 0.2 to 0.3 cycles for ER/18S, PgR/18S and HER1-4/18S.
Correlation between two different Qrt-PCR detection analyses
The quantitative mRNA expression levels of the six target genes measured in Basel and MRS correlated significantly with each other, as shown in Figure 1 . The squared correlation coefficients between the quantitative mRNA expression values ranged from a maximum of 0.98 (95% CI: 0.96-0.99) for ERα to a minimum of 0.84 for HER1 (95% CI: 0.77-0.89) and HER3 (95% CI: 0.76-0.88), as listed in Table III . The sample values detected by both laboratory units were in a 3-4 log range for all target genes corresponding to 10-13 PCR cycles. Expression values for all target genes are listed in Table IV. Most data points were found within the CI of the calculated Passing & Bablok regressions for all six target genes, revealing that the expression levels of the respective target genes measured in both laboratories were in significant agreement. The fact that the slope and the constant of the Passing & Bablok regressions are not equal to 1 and 0, respectively, is the consequence of different scales after transformation applied by the two groups. Despite the methodological differences high correlations were obtained, demonstrating both methods to be robust and reliable to quantify these biomarkers.
An interlaboratory control of Qrt-PCR measuring ERα and PgR with similar results was recently performed by de Cremoux et al (26) ; however, in this study all cDNA syntheses were performed in one laboratory.
Comparison of mRNA expression of ERα, PGR and HER2 with the respective protein expression levels
Subsequently, we compared the obtained mRNA expression profiles of ERα, PgR and HER2 with the corresponding quantitative protein levels previously measured (11, 20) in a subset of BC tissue samples (tumor set 1, n=100), since genomic and molecular studies described a good correlation between proteins and their gene expression patterns (27, 28) . Significant Spearman correlation coefficients (p<0.0001) were found for ERα: 0.83, PgR: 0.87 and HER2: 0.72 as shown in Figure 2 , which reconfirms the results of de Cremoux (15) . The correlations were less significant at low protein concentrations ( Fig. 2A and 2B) , which can be explained by less sensitive detection antibodies at lower protein concentration levels. Qrt-PCR exhibited a broad dynamic range and detected a 10-fold difference in transcripts even at low concentrations. The threshold values to define the hormone receptor status (positive or negative) of primary breast tumors according to the EIA assay were set at 20 fmol/mg total protein (29) . The scatter plot of HER2 protein and mRNA expression levels (both detected in Basel in Set 1a, n=50) revealed two clusters of data points discriminating tumors with and without HER2 overexpression (Fig. 2C) . Tumors with HER2 >260 ng/mg total protein were considered positive. This corresponds to a previously published cutoff value of 500 U/mg total protein (11) and to 16,400 U/µg rt RNA (simultaneous method of Basel). A saturation effect of EIA can be observed at higher HER2 protein concentrations, while Qrt-PCR allows more precise mRNA quantification with a larger dynamic range. Moreover, the main advantage of Qrt-PCR over EIA is that it needs much less tissue material due to the amplification of target sequences.
The inverse correlation found between ERα, PgR and HER2 at the protein level (4, 30) was also found at the mRNA expression level. The median values of ERα and PgR in HER2-positive tumors were 4191 U/µg rt RNA and 179 U/µg rt RNA, respectively, significantly lower as compared to the 15,979 U/µg rt RNA and 1459 U/µg rt RNA median values in HER2-negative tumors ( Fig. 3) .
Correlation between the HER2 status assessed either by Qrt-PCR or FISH
Current methods evaluating the HER2 status use IHC, ELISA, gene amplification by FISH and measurement of shedded HER2-antigen in serum by EIA (31) . Several investigators demonstrated that HER2negative BCs measured by IHC (Dako 0-1+) showed no amplification by FISH, whereas intermediate IHC staining (Dako 2+) tumors could be either FISH negative or positive (12, 32, 33) . Good concordance, however, was reported between FISH and Qrt-PCR on the DNA as well as the RNA level (34, 35) .
In this study the cutoff for HER2 status by Qrt-PCR, 16,400 U/µg rt RNA, was further investigated in Basel in 99 BC tissue samples (Set 2, Tab. I) versus gene amplification by FISH. As shown in Figure 4 , ROC analysis revealed good concordance between HER2 mRNA expression (simultaneous method Basel) and gene amplification by FISH (detected at the Institute of Pathology of University Hospital Basel). Of the 99 tumors examined with both techniques, 18 of the 19 FISH positives (sensitivity = 95%) and 75 of the 80 FISH negatives (specificity = 94%) were correctly classified. Disagreement occurred in six of the 99 cases (accuracy = 94%); the FISH-positive sample classified as negative according to Qrt-PCR analysis had an mRNA expression level of 10,430 U/µg rt-RNA; the five FISH-positive samples classified as negative by means of Qrt-PCR expressed values ranging from 17,260 to 35,790 U/µg rt-RNA. Noteworthily, three of the six misclassified samples were reported to be borderline negative by FISH with HER2/centromer 17 ratios ranging from 1.62 to 1.74. One of the misclassified samples showed gene amplification by polysomy of chromosome 17, which may lead to overexpression but results in a HER2/centromer 17 ratio of 1. The calculated chi-square test (χ 2 =62.5; p<0.0001) reconfirms a highly significant association between the HER2 status detected by FISH and Qrt-PCR mRNA expression levels. Comparable results were found by Ginestier et al (35) .
DISCUSSION
In this study we evaluated and compared the expression analysis of ERα, PgR, HER1, 2, 3 and 4 mRNAs using two Qrt-PCR methods, which differed in the following points: equipment (ABI Prism 7000 in Basel vs ABI Prism 7700 in MRS), primer positions and fluorescent dye (SYBR Green ® I vs gene-specific TaqMan ® probes). In addition, all genes in Basel were analyzed simultaneously as singlets on the same plate (simultaneous detection), whereas in Marseille, due to different primer annealing temperatures, each gene was analyzed separately, with up to 25 patient samples per plate (serial detection), in triplets. Whereas fluorescent hydrolysis probes only bind to specific templates and emit light only when cleaved by the polymerase, SYBR Green I usually has the disadvantage that it detects any kind of double-stranded DNA including non-specific products such as primer dimers (36) . Selected primers therefore have to be tested by dissociation curves before use in analysis to guarantee that no or only very few non-specific signals arise. Despite these technical and methodological differences, the mR-NA levels correlated strongly (r 2 =0.98-0.84) and significantly with one another for all six biomarkers analyzed.
The results of Qrt-PCR simultaneous detection were also found to strongly correlate with quantitative ERα, PgR and HER2 protein levels and in case of HER2 also with gene amplification by FISH. These findings are in agreement with those of other studies (15, 16, 35) and reconfirm the validity of the developed methodology.
Compared to IHC and EIA, Qrt-PCR has the great advantage that, by specific amplification of nucleic acid sequences, it enables us to obtain genetic information starting at a very low number of target copies even in small numbers of cells, such as obtained by fine-needle aspirates or core biopsies. There is no doubt that IHC allows simultaneous determination of histology and of proteins, as demonstrated by tissue arrays, and has great logistic advantages, but the results are semiquantitative and the analysis often varies due to subjective interpretation. Moreover, some proteins, like HER4, are very weakly expressed (19, 37) , others are poorly antigenic (e.g. HER3) (38) or it is very difficult to get antibodies working well in IHC (e.g urokinase plasminogen activator) (2); all of this makes the development of appropriate tests for protein expression detection very difficult.
In comparison to FISH, Qrt-PCR is less laborious and time consuming. With the SYBR Green I system performed in Basel, up to six patients could be analyzed in six to eight hours on a 96-well plate when detecting all target and control genes in duplets, whereas a single FISH analysis takes up to two days. Considering the growing role of neoadjuvant therapy, this is a point not to be underestimated. Moreover, the developed method presented in this study allows to assess up to 80 relevant genes in BC in a single PCR run, so that an individual tumor profile can be delivered within less than 24 hours of receipt.
In this study all analyses were performed in fresh frozen tissues, providing high-quality total RNA. However, most tumor samples are stored in paraffin blocks and the RNA in these tissues is strongly degraded (39) , which may lead to a loss of detectable mRNA because RNA breaks can occur in between the location of the primers used. To set up a system which works with RNA from paraffin-embedded tissue it is necessary to either choose primer couples generating very small amplicons so that at least some of the extracted RNA can be amplified (40, 41) , or use newly developed protocols for fixation that prevent strong degradation (42) .
Another way to bypass the problem of RNA degradation by tissue embedding in paraffin or the costs and logistic problems related to freezing and cryopreservation, is the use of stabilizing solutions such as RNA later™ (Qiagen, Hilden, Germany). Once this aqueous solution has penetrated the whole tissue, all RNases are inhibited and the tissue can be transported in a small reaction tube at room temperature and stored at -20°C for several months. It is important, however, that one of the three tissue dimensions does not exceed 5 mm to reduce the time of complete penetration and therefore the time in which RNAses are still active.
We showed that simultaneous expression analysis of cancer-relevant markers by Qrt-PCR using SYBR Green I generates results that are significantly correlated with those obtained by the classical Qrt-PCR method using specific TaqMan probes. Both Qrt-PCR methods are equally robust, but simultaneous analysis of more genes on the same plate using specific primers and SYBR Green I is faster than serial analysis of genes on different plates, rendering the method more appropriate for routine diagnostics. Moreover, this newly developed method is more cost-effective because there are no expenses for TaqMan probes.
In conclusion, due to its simplicity and the possibility to analyze several relevant cancer markers simultaneously on the same PCR plate, we are convinced that Qrt-PCR will become a suitable tool and a good alternative to current methodologies for routine BC analysis to discriminate between endocrine-responsive and treatmentresistant breast tumors and to improve the prognostic and predictive assessment of various BC types.
